Mayo Clinic Hepatobiliary SPORE Diversity Supplement Dr. Musa Gabere

候选人资格和多样性声明 穆萨·加贝雷博士是美国永久居民(绿卡号码：063-359-769)非洲人 下降。他在内罗毕大学完成了本科学业。然后他搬到了南非， 在那里他完成了研究生文凭，理学硕士和哲学博士。 Gabere博士对应用遗传学和生物信息学方法来识别常见的生物标志物感兴趣 这可以用来开发针对肝胆癌的靶向治疗。特别是，他将在 了解免疫病毒治疗对肝癌转录组的影响 免疫疗法。他将由Mitesh J.Borad博士(主要导师)、Richard G.Vile博士(联合导师)指导。 导师)和刘易斯·罗伯茨博士(共同导师)作为家长资助的一部分5P50CA210964-03(P.I.Richard G. 卑鄙)。 加贝雷博士的总体目标是从事癌症遗传学研究。Gabere博士将参与各种 在梅奥诊所接受培训。其中包括病毒疗法、免疫疗法、转化研究和伦理方面的培训。 此外，还有每周一次的癌症会议，在那里他可以学习并与梅奥癌症诊所互动 中心高级调查员。除此之外，加贝雷博士还将有机会与大型癌症进行合作 与肝癌和胰腺癌研究专家合作的遗传学数据。这些数据集包括但不包括 仅限于全基因组、外显子组、甲基组、代谢组和转录组等多种癌症 胆管癌。Gabere博士还将有机会指导和指导博士生和访问 科学家们将通过电子检测和功能检测来鉴定抗原。 多样性赠款还将使Gabere博士能够增加种族和少数民族的数量 参与生物标记物发现和临床试验。这将使Gabere博士能够通知和教育 少数群体对临床试验和早期癌症筛查的重要性。预计在收到通知后 通过多样性补充，Gabere博士将能够生成重要数据并申请外部资金，例如 在他第二年结束时，获得了CARE奖(R21)。

STATEMENT OF CANDIDATE ELIGIBILITY AND DIVERSITY Dr. Musa Gabere is a permanent resident of the United States (Green card number: 063-359-769) of African descent. He completed his undergraduate studies at the University of Nairobi. He then moved to South Africa, where he completed post-graduate diploma, Master of Science and Doctor of Philosophy. Dr. Gabere is interested in applying genetics and bioinformatics approaches to identify common biomarkers that can be used to develop targeted therapies for hepatobiliary cancers. In particular, he will train in understanding the transcriptome changes in hepatocarcinoma treated with immunovirotherapy, a new class of immunotherapeutic. He will be mentored by Dr. Mitesh J. Borad (Primary mentor), Dr. Richard G. Vile (Co- mentor), and Dr. Lewis Roberts (co-mentor) as part of the parent grant 5P50CA210964-03 (P.I. Dr. Richard G. Vile). The overall goal of Dr. Gabere is to pursue research in cancer genetics. Dr. Gabere will participate in various training in Mayo Clinic. These include training in virotherapy, immunotherapy, translational research and ethics. Additionally, there are weekly meetings in cancer, where he can learn and interact with Mayo Clinic Cancer Center senior investigators. In addition, to this, Dr Gabere will have the opportunity to work with large cancer genetics datasets with experts in liver and pancreatic cancer research. These datasets include but not restricted to whole genome, exome, methylome, metabolome and transcriptome for various cancers such as Cholangiocarcinoma. Dr Gabere will also have opportunity to mentor and supervise PhD students and visiting scientists to identify of antigens both in-silico and functional assays. The diversity grant will also allow Dr. Gabere to increase the number of racial and ethnic minorities who participate in biomarker discovery and clinical trials. This will allow Dr Gabere to inform and educate the minorities in the importance of clinical trials and early cancer screening. It is expected that upon receipt of the Diversity Supplement, Dr. Gabere will be able to generate vital data and apply for extramural funding, such as the care award (R21) at the end of his second year.